openPR Logo
Press release

ESR1-mutated Metastatic Breast Cancer Market Size was the highest in the US in 2023, accounting for ~USD 820 million, which is further expected to grow by 2034

12-05-2024 06:04 PM CET | Health & Medicine

Press release from: ABNewswire

ESR1-mutated Metastatic Breast Cancer Market Size was

DelveInsight's "ESR1-mutated Metastatic Breast Cancer Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Discover Key Insights into the ESR1 Mutated Metastatic Breast Cancer Market with DelveInsight's In-Depth Report @ ESR1 Mutated Metastatic Breast Cancer Market Size [https://www.delveinsight.com/sample-request/esr1-mutated-metastatic-breast-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the ESR1 Mutated Metastatic Breast Cancer Market Report

* In November 2024:- UNICANCER- Randomized, Open Label, Multicentric Phase III Trial to Evaluate the Safety and Efficacy of Palbociclib in Combination with HT Driven by CtDNA ESR1 Mutation Monitoring in ER+, HER2-negative Metastatic Breast Cancer Patients.
* The total diagnosed prevalent cases of ESR1-mutated Metastatic Breast Cancer in the United States was around 18,800 cases in 2023.
* The diagnosed prevalent cases of ESR1-mutated HR+ Metastatic Breast Cancer on first-line of treatment in the United States was estimated to be around 18,400 in 2023.
* Among the EU4 countries, Germany had the highest cases of ESR1 mutation in metastatic breast cancer, followed by France, whereas Spain accounted for the lowest number of cases in 2023.
* According to DelveInsight estimates, Japan reported approximately 45,000 cases of metastatic breast cancer, equivalent to around 13% of total cases in the 7MM.
* The leading Esr1-mutated Metastatic Breast Cancer Companies such as AstraZeneca, Olema Pharmaceuticals, Arvinas, Sermonix Pharmaceuticals, Roche, Eli Lilly and Company, H3 Biomedicine, Eisai, Pfizer, Sun Pharma Advanced Research Company, Zenopharm, and others
* Promising Esr1-mutated Metastatic Breast Cancer Therapies such as Elacestrant (RAD1901), Ibrance (Palbociclib), Rintodestrant (G1T48), SCO-120, ZB716, ARV-471, Lasofoxifene, H3B-6545, Giredestrant (RG6171, GDC-9545), Camizestrant (AZD9833), ZN-c5, OP1250, and others

Stay ahead in the ESR1 Mutated Metastatic Breast Cancer Therapeutics Market with DelveInsight's Strategic Report @ ESR1 Mutated Metastatic Breast Cancer Market Outlook [https://www.delveinsight.com/sample-request/esr1-mutated-metastatic-breast-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Esr1-mutated Metastatic Breast Cancer Epidemiology Segmentation

* Total Diagnosed Prevalent Cases of HR-Positive Breast Cancer
* Stage-specific Diagnosed Prevalent Cases of HR-positive Breast Cancer
* Total Diagnosed Prevalent Cases of Metastatic Breast Cancer
* Diagnosed Prevalent Cases of ESR1 Mutated Metastatic Breast Cancer
* Line-wise treatable cases of ESR1 Mutated Metastatic Breast Cancer

Download the report to understand which factors are driving ESR1 Mutated Metastatic Breast Cancer epidemiology trends @ ESR1 Mutated Metastatic Breast Cancer Prevalence [https://www.delveinsight.com/sample-request/esr1-mutated-metastatic-breast-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

ESR1 Mutated Metastatic Breast Cancer Marketed Drugs

* ORSERDU (elacestrant): Stemline Therapeutics (a wholly owned subsidiary of the Menarini Group)

ORSERDU (elacestrant) is a selective estrogen receptor degrader (SERD) out-licensed to Menarini Group. In January 2023, the US FDA approved ORSERDU for treating postmenopausal women or adult men with ER+, HER2, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Later in September 2023, the drug also got approved in Europe.

ESR1 Mutated Metastatic Breast Cancer Emerging Drugs

* Camizestrant (AZD9833): AstraZeneca

Camizestrant (AZD9833) is an oral SERD that has shown antitumor efficacy in a range of preclinical models of breast cancer. In June 2020, AstraZeneca initiated a Phase III clinical trial, SERENA-6, to evaluate the Safety and Efficacy of AZD9833 in combination with a CDK4/6 inhibitor (palbociclib or abemaciclib) for the treatment of patients with HR+ HER2 metastatic breast cancer with a detectable ESR1 mutation. As per Astrazeneca's pipeline, Camizestrant's + CDK4/6 inhibitor's estimated filing acceptance in 1st line HR+ HER2- ESR1m breast cancer is 2025. Apart from that, the indication for SERENA-6 has been granted Fast Track Designation (FTD) by the US FDA.

* Lasofoxifene: Sermonix Pharmaceuticals

Lasofoxifene is being investigated as a potent, bioavailable selective estrogen receptor modulator (SERM) with a differentiated safety profile that could prove useful in treating postmenopausal women and premenopausal women on ovarian suppression with locally advanced or metastatic ER+ breast cancer. Lasofoxifene's bioavailability and activity in estrogen receptor mutations could hold promise for patients who have acquired endocrine resistance due to ESR1 mutations, a common finding in the metastatic setting and an area of high unmet medical needs need.

Get In-Depth Knowledge on ESR1 Mutated Metastatic Breast Cancer Market Trends and Forecasts with DelveInsight @ ESR1 Mutated Metastatic Breast Cancer Treatment Market [https://www.delveinsight.com/sample-request/esr1-mutated-metastatic-breast-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

ESR1 Mutated Metastatic Breast Cancer Drugs Market Insights

The existing ESR1 treatment is mainly dominated by classes such as aromatase inhibitors, aromatase inhibitors + CDK4/6 inhibitors, and CDK4/6 + SERDs. For postmenopausal women with HR-positive, HER2-positive recurrent/Stage IV breast cancer, the preferred options available include fulvestrant with a CDK 4/6 inhibitor (palbociclib, ribociclib, and abemaciclib; category 1) or for those with tumor PIK3CA mutations, fulvestrant with alpelisib; everolimus with either an AI, tamoxifen or fulvestrant; monotherapy with fulvestrant, nonsteroidal or steroidal AI, or SERM. Estrogen receptor 1 (ESR1) activating mutations are frequently detected in patients with prior exposure to AIs. Tumors with these mutations are generally resistant to both AIs and tamoxifen. Certain tumors with these mutations retain sensitivity to fulvestrant. All may benefit from adding a CDK 4/6 inhibitor, mTOR-inhibitor, or alpelisib in combination with fulvestrant if the tumor has PIK3CA mutation.

ESR1-mutated Metastatic Breast Cancer Market Outlook

ESR1 mutations have increased, even with aromatase inhibitor (AI) therapy, indicating their adaptability to AI therapeutic conditions. In addition, the presence of ESR1 mutations has been correlated with a shorter time to treatment failure, as metastatic breast cancer (MBC) patients with ESR1 mutations exhibit an inadequate response to and shorter duration of effective endocrine control. Suppose AI treatment provides selection pressure for mutant-bearing clonal outgrowth in patients. In that case, the next option for therapy is likely a more effective selective estrogen receptor modulator (SERMs) and/or selective estrogen receptor downregulators (SERDs). Various studies have predicted that ESR1 mutations will still respond to SERMs or SERDs, though perhaps at a decreased sensitivity based on in vitro, xenograft, and PDX preclinical models. In the past 5 years, agents that have become available are CDK4/6 inhibitors.

Get In-Depth Knowledge on ESR1 Mutated Metastatic Breast Cancer Market Trends and Forecasts with DelveInsight @ ESR1 Mutated Metastatic Breast Cancer Treatment Market [https://www.delveinsight.com/sample-request/esr1-mutated-metastatic-breast-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Esr1-mutated Metastatic Breast Cancer Therapies and Key Companies

* Elacestrant (RAD1901): Radius Pharmaceuticals/Berlin-Chemie (Menarini Group)
* Ibrance (Palbociclib): Pfizer
* Rintodestrant (G1T48): G1 Therapeutics, Inc.
* SCO-120: Sun Pharma Advanced Research Company
* ZB716: Zenopharm
* ARV-471: Arvinas
* Lasofoxifene: Sermonix Pharmaceuticals
* H3B-6545: H3 Biomedicine/Eisai
* Giredestrant (RG6171, GDC-9545): Roche
* Camizestrant (AZD9833): AstraZeneca
* ZN-c5: Zentalis Pharmaceuticals
* OP1250: Olema Pharmaceuticals

Scope of the ESR1 Mutated Metastatic Breast Cancer Market Report

* Study Period: 2020-2034
* Coverage: 7MM
* Esr1-mutated Metastatic Breast Cancer Companies- AstraZeneca, Olema Pharmaceuticals, Arvinas, Sermonix Pharmaceuticals, Roche, Eli Lilly and Company, H3 Biomedicine, Eisai, Pfizer, Sun Pharma Advanced Research Company, Zenopharm, and others
* Esr1-mutated Metastatic Breast Cancer Therapies- Elacestrant (RAD1901), Ibrance (Palbociclib), Rintodestrant (G1T48), SCO-120, ZB716, ARV-471, Lasofoxifene, H3B-6545, Giredestrant (RG6171, GDC-9545), Camizestrant (AZD9833), ZN-c5, OP1250, and others
* Esr1-mutated Metastatic Breast Cancer Therapeutic Assessment: - Esr1-mutated Metastatic Breast Cancer current marketed and Esr1-mutated Metastatic Breast Cancer emerging therapies
* Esr1-mutated Metastatic Breast Cancer Market Dynamics: Esr1-mutated Metastatic Breast Cancer market drivers and Esr1-mutated Metastatic Breast Cancer market barriers
* Esr1-mutated Metastatic Breast Cancer Unmet Needs, KOL's views, Analyst's views, Esr1-mutated Metastatic Breast Cancer Market Access and Reimbursement

Table of Content

1 Key Insights

2 Report Introduction

3 Executive Summary

4 Key Events

5 Epidemiology and Market Forecast Methodology

6 ESR1-Mutated Metastatic Breast Cancer Market Overview at a Glance in the 7MM

7 Disease Background and Overview

8 Epidemiology and patient Population of the 7MM

9 Patient Journey

10 Key Endpoints in ESR1-mutated Metastatic Breast Cancer

11 Key Cross Competition of Drugs

12 Marketed Drug

13 Emerging Drugs

14 ESR1-mutated Metastatic Breast Cancer: The 7MM Market Analysis

15 Unmet Needs

16 SWOT Analysis

17 KOL Views

17.1 KOL Interviews

18 Market Access and Reimbursement

19 Appendix

20 DelveInsight Capabilities

21 Disclaimer

22 About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=esr1mutated-metastatic-breast-cancer-market-size-was-the-highest-in-the-us-in-2023-accounting-for-usd-820-million-which-is-further-expected-to-grow-by-2034]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release ESR1-mutated Metastatic Breast Cancer Market Size was the highest in the US in 2023, accounting for ~USD 820 million, which is further expected to grow by 2034 here

News-ID: 3774376 • Views:

More Releases from ABNewswire

Best Deals on 2025 Milwaukee Bucks NBA Tickets - Use Promo CITY10 Online at CapitalCityTickets.com
Best Deals on 2025 Milwaukee Bucks NBA Tickets - Use Promo CITY10 Online at Capi …
Get the best deals on 2025 Milwaukee Bucks tickets at CapitalCityTickets.com! Choose from a wide selection of seat levels and enjoy even greater savings by applying promo code CITY10 at checkout. Secure your tickets now and cheer on the Bucks live at Fiserv Forum or on the road-while seats last! Looking for the best deals on Milwaukee Bucks NBA tickets for the 2025-26 season? You can score affordable tickets to see
Affordable Montreal Canadiens Bell Centre Tickets Online - Save with Promo Code CITY10 on the Best Site CapitalCityTickets.com
Affordable Montreal Canadiens Bell Centre Tickets Online - Save with Promo Code …
Score affordable Montreal Canadiens tickets at Bell Centre! Use promo code CITY10 at CapitalCityTickets.com to save on your seats. Compare ticket options, find the best views, and secure your spot to watch the Canadiens live. Don't miss top NHL action-grab discounted tickets today and enjoy thrilling hockey games without overspending! As the 2025-26 NHL season ignites, the Montreal Canadiens are gearing up to light up the Bell Centre with their signature
Central Florida Notary Express, LLC Expands 24/7 Notary and Mobile Notary Services Across Greater Orlando
Central Florida Notary Express, LLC Expands 24/7 Notary and Mobile Notary Servic …
Winter Park, FL - Central Florida Notary Express, LLC, a 24/7 provider of notary and mobile notary services and certified loan signings, announced expanded same-day coverage across the Greater Orlando area, including Orlando, Winter Park, Maitland, Casselberry, Winter Springs, DeLand, DeBary, Deltona, Sanford, and Lake Mary. The company offers on-site and curbside notarization for jurats, acknowledgments, power of attorney (POA), wills, health care surrogate forms, copy certifications, and real-estate loan
Stafili Wine Cafe Brings the Heart of Greece to New York City - A Sophisticated Destination for Wine Lovers and Food Enthusiasts
Stafili Wine Cafe Brings the Heart of Greece to New York City - A Sophisticated …
Nestled in the vibrant neighborhoods of West Village and Tribeca, Stafili Wine Cafe is redefining New York's dining scene with an unforgettable Greek-inspired experience that blends exceptional wines, authentic Mediterranean cuisine, and an inviting, intimate atmosphere. Whether you're seeking a cozy date night, an after-work escape, or a refined venue for social gatherings, Stafili promises an indulgent journey through the flavors, aromas, and spirit of Greece - without ever leaving

All 5 Releases


More Releases for Breast

Breast Health Monitoring App Market to Witness a Pronounce Growth during 2024-20 …
The latest market intelligence report published by WMR with the title "Global Breast Health Monitoring App Market 2024, Growth Opportunities, and Forecast" provides actionable insights on Healthcare and Pharmaceuticals industry. The report provides demand analysis, industry insights, competitive intelligence, and customer database. The Research report on Breast Health Monitoring App Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y
Primary Breast Cancer Survivor Phil Alderson Shines Light on Male Breast Cancer …
FOR IMMEDIATE RELEASE Primary Breast Cancer Survivor Phil Alderson Shines Light on Male Breast Cancer During Breast Cancer Awareness Month Liverpool, UK - October, 2023 - Phil Alderson, a primary survivor of male breast cancer, is taking bold steps this Breast Cancer Awareness Month to raise awareness of this often overlooked aspect of the disease. With a homemade cardboard sign that reads "Check Your Pecks," Phil has taken to the streets of
Breast Health Monitoring App Market Recent Trends, In-depth Analysis, Size, and …
According to The Worldwide Market Reports, the Latest research report on "Breast Health Monitoring App Market Size, Revenue, Global Analysis, and Forecast 2023 to 2030" The Breast Health Monitoring App Market research study is a professional report with premium insights into the size of the business, current patterns, drivers, risks, potential outcomes, and major segments. The Industry Report forecasts the future growth of the market based on precise assumptions. Furthermore,
Breast Pumps Market - Nurturing Convenience: Revolutionizing Breast Pump Technol …
Newark, New Castle, USA - new report, titled Breast Pumps Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Breast Pumps market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Breast Pumps market. The report offers an overview of the market, which
Breast Imaging Market by Breast Ultrasound, Breast MRI, Automated Whole-Breast U …
Growth of breast imaging market driven by factors like rising incidence of breast cancer globally, growing government investments and funding for breast cancer treatment and related research, increasing awareness about early detection of breast cancer, rising geriatric population, technological advancements in breast imaging modalities, and launch of advanced breast imaging systems capable of detecting cancer in women with dense breast tissues. Download Free PDF Brochure on Brest Imaging Market Report Now
Breast Implants Market Report 2018: Segmentation by Product (Silicone Breast Imp …
Global Breast Implants market research report provides company profile for Allergan, Mentor Worldwide LLC, Hans biomed, Establishment Labs, Polytech Health & Aesthetics, Sientra, Inc., GC Aesthetics, Cereplas and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to